Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13222026 | 0.90 | ALDH1A1 (0.36) | MAPTALDH1A1HPGDSMN1; SMN2TSHR | |
| SCHEMBL1654291 | 0.82 | ALDH1A1 (0.37) | MAPTALDH1A1TSHRL3MBTL1MEN1 | |
| SCHEMBL1653342 | 0.82 | ALDH1A1 (0.37) | MAPTALDH1A1HPGDSMN1; SMN2TSHR | |
| SCHEMBL13675080 | 0.81 | MAPT (0.36) | MAPTALDH1A1HPGDSMN1; SMN2TSHR | |
| SCHEMBL1653269 | 0.81 | ALDH1A1 (0.34) | MAPTALDH1A1HPGDSMN1; SMN2TSHR | |
| SCHEMBL1653268 | 0.81 | MAPT (0.33) | MAPTALDH1A1TSHRL3MBTL1MEN1 | |
| SCHEMBL1653276 | 0.80 | HIF1A (0.40) | MAPTALDH1A1SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL13348341 | 0.76 | ALDH1A1 (0.38) | MAPTALDH1A1HPGDSMN1; SMN2TSHR | |
| SCHEMBL1654482 | 0.75 | ALDH1A1 (0.34) | MAPTALDH1A1HPGDSMN1; SMN2TSHR | |
| SCHEMBL1654068 | 0.72 | ALDH1A1 (0.39) | MAPTALDH1A1SMN1; SMN2TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247746-A1 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247746-A1 | Fused heterocyclic compound | GCKR, GCK, GPR119 | MAPT 4377/4885ALDH1A1 372/4885HPGD 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.